Strategy

We carefully select promising preclinical candidates and then work to achieve clinical proof of concept and create molecules on the cusp of becoming a drug. Here’s how we do it:

  • Translational Expertise

    Our founders have deep, highly-credentialed experience designing innovative clinical development plans and executing rigorous clinical trials, including antibody-drug conjugates, novel biologics, and innovative small molecules.

  • Industry Network

    We are veterans in global oncology drug research, development, commercialization and deal-making, and have built an extensive professional network within the worldwide oncology community. This enables us to forge win-win licensing partnerships for the most promising assets and license out proven therapies to our global pharmaceutical network.

Company Pipeline

Program

Modality / MOA

Indication

Discovery

Pre-Clinical

Phase I

OnCusp Rights

CUSP06

CDH6 Antibody
Drug-Conjugate (ADC)

Solid Tumors

Ex-China

CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a highly stable and homogenous ADC. The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased “bystander effect” compared to competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight.

CUSP03

Small Molecule Inhibitor/
RNA Modulator

Hematological + Solid Tumors

Ex-China

CUSP03 is a small molecule inhibitor to an RNA modifying enzyme that plays a critical role in driving large subsets of a hematologic malignancy, as well as a potential role in multiple solid tumors. This program is in lead optimization stage.

CUSP02

Bispecific/
Tumor Micro-Environment

Hematological + Solid Tumors

Global

CUSP02 is a novel bispecific antibody that is designed to have important anti-tumor, immune-targeting and anti-angiogenic properties. This program is currently in early discovery.

Swipe To View